Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (b-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: vorsetuzumab, vorsetuzumab mafodotin, mdx-1411 +1 | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 14876
Sealed predictions
- CD70 in dopamine neurons, braak-0.17 (p 0.663) → +0.00 (p 1.000)receipt 14883
Swarm cases
receipt 14883: CD70 in dopamine neurons, braak
- power
- full sample -0.13 (p 0.615, n 18), 95% CI -0.56 to +0.36. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.16 (p 0.526, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.23 (p 0.365, n 18). could be the mix.
- skeptic
- leave-one-out range -0.25 to -0.03, sign flips 0; without severely affected donors -0.13 (p 0.615, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD70 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts